Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M. Ismael G, et al. Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. doi: 10.1016/j.hoc.2007.03.003. Hematol Oncol Clin North Am. 2007. PMID: 17512447 Review.
Molecular profiling of a tumor of unknown origin.
Ismael G, de Azambuja E, Awada A. Ismael G, et al. N Engl J Med. 2006 Sep 7;355(10):1071-2. doi: 10.1056/NEJMc061533. N Engl J Med. 2006. PMID: 16957161 No abstract available.
Current management of ovarian carcinosarcoma.
Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D'Hondt V, Piccart M, Awada A. Mano MS, et al. Among authors: ismael g. Int J Gynecol Cancer. 2007 Mar-Apr;17(2):316-24. doi: 10.1111/j.1525-1438.2006.00760.x. Int J Gynecol Cancer. 2007. PMID: 17362309 Review.
Novel cytotoxic drugs: old challenges, new solutions.
Ismael GF, Rosa DD, Mano MS, Awada A. Ismael GF, et al. Cancer Treat Rev. 2008 Feb;34(1):81-91. doi: 10.1016/j.ctrv.2007.08.001. Epub 2007 Oct 1. Cancer Treat Rev. 2008. PMID: 17905518 Review.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Ismael G, et al. Lancet Oncol. 2012 Sep;13(9):869-78. doi: 10.1016/S1470-2045(12)70329-7. Epub 2012 Aug 9. Lancet Oncol. 2012. PMID: 22884505 Clinical Trial.
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.
Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, Ismael G. Jackisch C, et al. Among authors: ismael g. Ann Oncol. 2015 Feb;26(2):320-5. doi: 10.1093/annonc/mdu524. Epub 2014 Nov 17. Ann Oncol. 2015. PMID: 25403587 Free article. Clinical Trial.
27 results